SciELO - Scientific Electronic Library Online

vol.27 issue3Vacunas en melanomaFiebre secundaria a citostáticos author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links


Oncología (Barcelona)

Print version ISSN 0378-4835


BARCO MORILLO, E. del et al. Experiencia del Hospital Universitario de Salamanca en el tratamiento sistémico adyuvante del cáncer de mama locorregional: Resultados de un protocolo asistencial tras 7 años de seguimiento. Oncología (Barc.) [online]. 2004, vol.27, n.3, pp.28-38. ISSN 0378-4835.

PURPOSE: To evaluate the effectiveness of the adjuvant systemic therapy of breast cancer in terms of disease-free survival (DFS), overall survival (OS) and toxicity. MATERIAL AND METHODS: We made a prospective study in a cohort of 308 patients. We designed four different escalating schedule treatments in relation to risk groups, prognostic factors and biologic factors. We used tamoxifen or anthracycline alone, or tamoxifen combined with anthracycline at two different doses. RESULTS: The median following up was seven years. The findings for DFS ± s.d. and OS ± s.d. were as follows: node-negative patients, 86 ± 2% and 91 ± 2%, and node-positive patients, 64 ± 3% and 82 ± 3%, respectively. For the overall group, the results were 75 ± 2% DFS and 87 ± 1% OS. The main toxicity was hematological in patients receiving chemotherapy. CONCLUSIONS: The escalating schedule treatment adjusted to patients in relation to risk group and prognostic factors optimizes the selection of chemotherapy agents and dose-intensity schedule, avoiding unnecessary toxicities and obtaining a high effectiveness in terms of DFS.

Keywords : Breast cancer; Adjuvant treatment; Tamoxifen; Chemotherapy; Anthracycline.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License